Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 107 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Pharmacyclics LLC. Clear all
Completed Phase 2 Interventional

Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer

NCT00134186
View directory record Official record
Conditions
Carcinoma, Renal Cell, Urogenital Neoplasms, Urologic Neoplasms, Kidney Neoplasms
Interventions
motexafin gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2007 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer

NCT02321540
View directory record Official record
Conditions
Lung Cancer
Interventions
Ibrutinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)

NCT01292135
View directory record Official record
Conditions
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
PCI-32765
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Boston, Massachusetts • New Hyde Park, New York • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 2 Interventional Results available

Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)

NCT03207555
View directory record Official record
Conditions
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Interventions
Ibrutinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma

NCT00724984
View directory record Official record
Conditions
Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin
Interventions
PCI-24781
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Lafayette, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2014 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer

NCT02899078
View directory record Official record
Conditions
Metastatic Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
Ibrutinib, Nivolumab
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 2 Interventional

A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma

NCT01779791
View directory record Official record
Conditions
Lymphoma
Interventions
PCI-32765 (Ibrutinib)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
20
States / cities
Los Angeles, California • Stanford, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 1 Interventional

Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients

NCT00562224
View directory record Official record
Conditions
Neoplasms by Site, Lymphoma, Non-hodgkin, Hodgkin Disease, Multiple Myeloma, Leukemia, Lymphocytic, Chronic
Interventions
PCI-24781
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Greenbrae, California • Chicago, Illinois • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL

NCT01752426
View directory record Official record
Conditions
Leukemia
Interventions
Heavy Water (2H2O), PCI-32765
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

NCT01974440
View directory record Official record
Conditions
Lymphoma
Interventions
Bendamustine, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, PCI-32765 (Ibrutinib), Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
32
States / cities
Gilbert, Arizona • Campbell, California • Duarte, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Jul 23, 2026, 1:27 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

NCT03646461
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
Ibrutinib 560mg PO daily (Imbruvica), Cetuximab, Nivolumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 1:27 AM EDT
Terminated Phase 3 Interventional Results available

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

NCT02703272
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Ibrutinib, Rituximab, Ifosfamide, Carboplatin, Etoposide, Vincristine, Idarubicin, Dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
1 Year to 30 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
17
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Jul 23, 2026, 1:27 AM EDT
Active, not recruiting Phase 1 Interventional

Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

NCT03422393
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Venetoclax, Ibrutinib
Drug
Lead sponsor
Michael Choi
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 1 Interventional

Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

NCT02553941
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Refractory Anemia With Excess Blasts in Transformation, Secondary Myelodysplastic Syndrome
Interventions
Azacitidine, Ibrutinib
Drug
Lead sponsor
Brian Jonas
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Jul 23, 2026, 1:27 AM EDT
Terminated Phase 2 Interventional Results available

Ibrutinib and Rituxan for Chronic GVHD

NCT04235036
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
Rituximab, Ibrutinib
Drug
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL

NCT01217749
View directory record Official record
Conditions
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocyctic Leukemia, Richter's Transformation
Interventions
PCI-32765, ofatumumab
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Jul 23, 2026, 1:27 AM EDT
Approved For Marketing No phase listed Expanded access

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

NCT01833039
View directory record Official record
Conditions
Relapsed or Refractory Mantle Cell Lymphoma
Interventions
Ibrutinib
Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT02077166
View directory record Official record
Conditions
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
Ibrutinib, Lenalidomide, Rituximab
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
22
States / cities
Birmingham, Alabama • Gilbert, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

NCT02195869
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
10
States / cities
Duarte, California • San Francisco, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Jul 23, 2026, 1:27 AM EDT
Terminated Phase 1 Interventional

Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

NCT00080028
View directory record Official record
Conditions
Head and Neck Cancer, Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer
Interventions
Motexafin Gadolinium Injection
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Durham, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2007 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food

NCT01969266
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Treatment A: PCI-32765, Treatment B: PCI-32765
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Jul 23, 2026, 1:27 AM EDT
Recruiting Phase 2 Interventional

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

NCT05963074
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Venetoclax
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
32
States / cities
Cerritos, California • Los Alamitos, California • San Luis Obispo, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

NCT01855750
View directory record Official record
Conditions
Lymphoma
Interventions
Ibrutinib, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (or equivalent)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
44
States / cities
Tucson, Arizona • Greenbrae, California • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jul 23, 2026, 1:27 AM EDT
Completed Phase 1Phase 2 Interventional

Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00290004
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Leukemia, Lymphoma
Interventions
motexafin gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Los Angeles, California • San Diego, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2008 · Synced Jul 23, 2026, 1:27 AM EDT